Nuakea Therapeutics

Nuakea Therapeutics appears to have been a very early-stage private biotech company in Massachusetts. Publicly available evidence is sparse, but the company was identified as a semi-finalist in Agilent's 2021 Golden Ticket competition at LabCentral, indicating it was operating in the biotech startup ecosystem at that time. Corporate registry records identify the legal entity as NUAKEA THERAPEUTICS LLC in Massachusetts and indicate that the entity is now inactive. No reliable public sources were found describing a disclosed pipeline, therapeutic targets, modality focus, financing history, or commercial products. Based on the limited evidence available, Nuakea Therapeutics should be treated as a defunct or inactive early-stage biotech rather than an operating clinical-stage company.